Amongst tariff disputes with the United States, there is some good news for those in China who suffer from, or have increased chances around contracting shingles. The country has recently approved shingles vaccine, Shringrix, manufactured by GlaxoSmithKline (GSK), for use within the nation. The shot helps to prevent the condition in those aged 50 and over.
Shringrix showed up on a list of 48 medicines recently deemed ‘clinically urgent’ within the country after testing trials revealed a 90% efficacy rate, where this prompted the National Medical Products Administration (NMPA) to place its stamp of approval on it. The clinical trial phase III confirmed the immunogenicity, efficacy, and safety of the shot within over 38,000 individuals.
GSK has relayed a statement, noting that in order to meet product demands, it currently is heavily investing in its capabilities around production of the Shringrix shingles vaccine.
The shot will be introduced within China in stages, starting in early 2020. This is to help decrease any disruption when it comes to worldwide supply of the vaccine. Shringrix is licensed for use in the United States of America, Europe, Japan, Australian, as well as Canada.
When it comes to the United States, Shringrix is still on the website for the U.S. The Centers for Disease Control and Prevention (CDC), as it is currently dealing with shortages and delay, due to popular demand.
European Pharmacy Review revealed that a facility in France was approved by the U.S. Food and Drug Administration (FDA) earlier in 2019, to produce the vaccine, in hopes that it could help enhance availability, thanks to the ever-growing need and want for the shot.
Chief Medical Officer, GSK Vaccines, Thomas Breuer recently stated that the company was looking forward to working with agencies in China to help provide the benefits the shot brings, to local communities.
Here’s hoping this vaccine can help those within this country avoid the suffering that can be caused when this condition surfaces.